Evidence map›Paper›PMID 34907043›Full record

ArticleBMJ open2021

Randomised controlled trial to investigate optimal antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: a study protocol of the OPTIMA-AF trial.

Yohei Sotomi, Ken Kozuma, Kosuke Kashiwabara, Yoshiharu Higuchi, Kenji Ando, Yoshihiro Morino, Junya Ako, Kengo Tanabe, Takashi Muramatsu, Gaku Nakazawa and 3 more

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Add-on antiplatelet therapy in anticoagulated patients with atrial fibrillation.International journal of cardiology. Heart & vasculature · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 11 institutions in 1 country.

Yohei SotomiDepartment of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.ORCID 0000-0002-7564-2978
Ken KozumaDepartment of Medicine, Division of Cardiology, Teikyo University School of Medicine, Tokyo, Japan.
Kosuke KashiwabaraDepartment of Biostatistics, School of Public Health, University of Tokyo, Tokyo, Japan.
Yoshiharu HiguchiDepartment of Cardiology, Osaka Police Hospital, Osaka, Japan.
Kenji AndoDepartment of Cardiology, Kokura Memorial Hospital, Fukuoka, Japan.
Yoshihiro MorinoDepartment of Internal Medicine, Division of Cardiology, Iwate Medical University, Iwate, Japan.
Junya AkoDepartment of Cardiovascular Medicine, Kitasato University School of Medicine, Kanagawa, Japan.
Kengo TanabeDepartment of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan.
Takashi MuramatsuDepartment of Cardiology, Fujita Health University School of Medicine, Aichi, Japan.
Gaku NakazawaDepartment of Cardiology, Kinki University Hospital, Osaka, Japan.
Shungo HikosoDepartment of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.ORCID 0000-0003-2284-1970
Yasushi SakataDepartment of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan yasushisk@cardiology.med.osaka-u.ac.jp.ORCID 0000-0002-5618-4721
OPTIMA-AF Investigators
The University of Osaka · JPFujita Health University · JPIwate Medical University · JPKindai University Hospital · JPKitasato University · JPKokura Memorial Hospital · JPMitsui Memorial Hospital · JPOsaka City University · JPOsaka Police Hospital · JPTeikyo University · JPThe University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe optimal antithrombotic strategy for patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) is uncertain. For patients with non-AF, many trials are now evaluating short 1-month dual antiplatelet therapy. In patients with AF undergoing PCI, in contrast, short dual therapy (P2Y METHODS AND ANALYSIS: The OPTIMA-AF trial ( ETHICS AND DISSEMINATION: This study received approval from the Certified Review Board of Osaka University (a certified research ethics committee by the Japanese Clinical Research Act). The findings will be disseminated through peer-reviewed publications and conference presentations. TRIAL REGISTRATION NUMBER: Japan Registry of Clinical Trials: jRCTs051190053; Pre-results.

Indexed as

Atrial FibrillationDrug-Eluting StentsPercutaneous Coronary InterventionAnticoagulantsDrug Therapy, CombinationFibrinolytic AgentsHumansPlatelet Aggregation InhibitorsProspective StudiesRandomized Controlled Trials as TopicTreatment OutcomeAnticoagulantsFibrinolytic AgentsPlatelet Aggregation Inhibitorscardiologycoronary interventionthromboembolism

Identifiers

PMID34907043
PMCPMC8671924
OpenAlexW4200057941

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.